The apelin peptides as putative targets in cardiovascular drug discovery and development.
Apelin is a recently isolated peptide that appears to act as an endogenous ligand for the previously orphaned G-protein-coupled receptor APJ. A number of studies have reported cardiovascular actions of apelin, including changes in the blood pressure and potent inotropic actions. Furthermore, perturbations of both apelin and APJ within the myocardial tissue and circulating levels of the peptide have been reported in a number of cardiovascular disease states. Taken together, these studies suggest a role for apelin in the pressure/volume homeostasis and in the pathophysiology of cardiovascular diseases. However, findings in the literature to date are, at times, disparate. This review highlights key areas where further work is required to clarify the role of apelin/APJ in both normal physiology and pathophysiology. Nonetheless, preliminary evidence suggests that the manipulation of this receptor/ligand peptide system may be a target for drug development, thereby offering a therapeutic benefit in cardiovascular diseases.